Antibody Engineering and Therapeutics Conference

I was invited to speak at the Antibody Engineering and Therapeutics Conference (presenting mine and Matt’s recently published epitope profiling paper), in San Diego (December 12th – 16th). Unfortunately, the pandemic had other ideas so I decided not to travel but luckily the conference was hybrid. 

The conference included 1 day of pre-conference workshops and 4 days of presentations from academic and industry, with livestreaming of the initial keynotes (including one from Charlotte). Remaining talks were recorded and made available after the conference. I’ve highlighted a few of my favourite talks and conference themes, with links to papers where available.

Naturally, a lot of the presented research related to covid-19. I was speaking in the ‘Antibody Repertoires and Covid-19’ session, where there were interesting presentations from Professor Eline Luning Prak from the University of Pennsylvania and Elaine Chen from Vanderbilt University analysing antibody responses in covid-recovered individuals, and comparing vaccine responses in covid-recovered vs covid-naiive individuals. Other talks around SARS-CoV-2 vaccines included Dr Laura Walker from Adimab/Adagio Therapeutics comparing BCR repertoire responses to different types of vaccinations, and the effect of using different booster types.

Continue reading →

Model validation in Crystallographic Fragment Screening

Fragment based drug discovery is a powerful technique for finding lead compounds for medicinal chemistry. Crystallographic fragment screening is particularly useful because it informs one not just about whether a fragment binds, but has the advantage of providing information on how it binds. This information allows for rational elaboration and merging of fragments.

However, this comes with a unique challenge: the confidence in the experimental readout, if and how a fragment binds, is tied to the quality of the crystallographic model that can be built. This intimately links crystallographic fragment screening to the general statistical idea of a “model”, and the statistical ideas of goodness of fit and overfitting.

Continue reading →

snakeMAKE better workflows with your code

When developing your pipeline for processing, annotating and/or analyzing data, you will probably find yourself needing to continuously re-run it, as you play around with your code. This can become a problem when working with long pipelines, large datasets and cpu’s begging you not to run some pieces of code again.

Luckily, you are not the first one to have been annoyed by this and other related struggles. Some people were actually so annoyed that they created Snakemake. Snakemake can be used to create workflows and help solve problems, such as the one mentioned above. This is done using a Snakefile, which helps you split your pipeline into “rules”. To illustrate how this helps you create a better workflow, we will be looking at the example below.

Continue reading →

Highlights from the European Antibody Congress 2021

Last month, I was fortunate enough to be able to attend (in person!) and present at the Festival of Biologics European Antibody Congress (9-11 November, 2021) in Basel, Switzerland. The Festival of Biologics is an annual conference, which brings together researchers from industry and academia. It was an excellent opportunity to learn about exciting research and meet people working in the antibody development field.

Here are some of my highlights from the European Antibody Congress, with a focus on antibody design and engineering:

Continue reading →

Targeted protein degradation phenotypic studies using HaloTag CRISPR/Cas9 endogenous target tagging and HaloPROTAC

Biologists currently have several options in their arsenal when it comes to gene silencing. if you want to completely vanquish the gene in question, you can use CRISPR to knock the gene out completely. This is a great way to completely eliminate the gene, and hence compare cell phenotypes with and without the gene, but it’s less good if the gene is essential and the cells won’t grow without it in the first place. 

Otherwise you can use RNA interference, where small pieces of RNA that complement the mRNA for that gene are introduced to the cell, with the overall effect of blocking transcription of that gene’s mRNA, hence silencing it. However, this method suffers from side effects and varying levels of gene knockdown efficiency. Moreover, it does not vanquish existing protein, it just stops more from being produced.

Continue reading →

Packaging with Conda

If you are as happy for the big snake as I am, you have probably wondered how you can create a Conda package with your amazing code. Fear not, in the following text you will learn how to make others go; 

conda install -c coolperson amazingcode

Roughly, the only thing needed to create a Conda package, is a ‘meta.yaml’ file specific for your code. This file contains all the metadata needed to create your package and is highly customizable. While this means the meta.yaml can be written to allow your Conda package to work on any operating system and with any dependencies (doesn’t have to be python) it can be annoying to write from scratch (here is a guide for manually writing this file). Since we just want to create a simple Conda package, we will in this guide avoid fiddling around with the meta.yaml file and instead create the file based on a PyPI package. This will also give you a nice template, if you later need to adapt your meta.yaml file.
Note: Conda packages can also be made from GitHub repositories, which is likely favorable in most cases, but it also requires some manual work on the meta.yaml.

1. Create a PyPI package of your code

Continue reading →

Five Nuggets of Wisdom for Chairing at a Conference

I recently spoke at the Festival of Biologics 2021 conference in Basel (in-person, just in time!), and was lucky enough to be offered the chance to chair a session of talks. As this was the first time I’d ever been asked to do this, I asked Charlotte for some hints to make things go more smoothly. I found her advice very useful, so I thought I’d share it here for other first-time “chairers”!

Continue reading →

New review on BCR/antibody repertoire analysis out in MAbs!

In our latest immunoinformatics review, OPIG has teamed up with experienced antibody consultant Dr. Anthony Rees to outline the evidence for BCR/antibody repertoire convergence on common epitopes post-pathogen exposure, and all the ways we can go about detecting it from repertoire gene sequencing data. We highlight the new advances in the repertoire functional analysis field, including the role for OPIG’s latest tools for structure-aware antibody analytics: Structural Annotation of AntiBody repertoires+ (SAAB+), Paratyping, Ab-Ligity, Repertoire Structural Profiling & Structural Profiling of Antibodies to Cluster by Epitope (‘SPACE’).

Continue reading →

A logical brain teaser to derail your afternoon

Brain teasers have a strange power. For many they evoke nothing more than a mild and transient sense of curiosity. But for a certain subset of people they create an irresistible intellectual temptation which even needs to actively be avoided at times as not to completely derail conversations and take over whole afternoons.

For better or worse, I am in the camp of people who are highly susceptible to brain teasers. I just love them too much. More than once in my lifetime I had to ask a friend not to tell me about a particular brain teaser they had heard about because I knew it would inevitably take over my mind and send me down an almost hypnotic spiral of thoughts whose only escape would be finding the solution.

While brain teasers can admittedly turn into ridiculously powerful distractions for some of us, they are not necessarily a waste of time. They have high recreational value and help the mind to enter a playful and creative state. They serve as mental gymnastics to directly train logical thinking skills, and logical thinking is arguably one of the most powerful transferable skills that exists. And last but not least, brain teasers are canonically used nowadays in job interviews at some of the worlds top employers (Google, Facebook, Microsoft, prestigious hedge funds, …).

In this post, I will present one of my favourite brain teasers to see if I can get you hooked. It is a slightly modified and self-contained version of the so-called pirate game. You can find the solution at the end of the page. Enjoy responsibly! Continue reading →

Benchmarks in De Novo Drug Design

I recently came across a review of “De novo molecular drug design benchmarking” by Lauren L. Grant and Clarissa S. Sit where they highlighted the recently proposed benchmarking methods including Fréchet ChemNet Distance [1], GuacaMol [2], and Molecular Sets (MOSES) [3] together with its current and future potential applications as well as the steps moving forward in terms of validation of benchmarking methods [4].

From this review, I particularly wanted to note about the issues with current benchmarking methods and the points we should be aware of when using these methods to benchmark our own de novo molecular design methods. Goal-directed models are referring to de novo molecular design methods optimizing for a particular scoring function [2].

Continue reading →